 Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia.This makes ofatumumab the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.Its only indication that has received regulatory approval is chronic lymphocytic leukemia (CLL).